Rosetta Genomics announced earlier this week the availability of its third MicroRNA-based diagnostic test called miRview(TM) meso.
The test is the first that can diagnose mesothelioma from other types of cancers found in the lung. Harvey Pass, MD, Division Chief for Thoracic Surgery and Thoracic Oncology at the New York University Langone Medical Center said, “Ruling out Mesothelioma from lung cancer for individuals that were exposed to asbestos can be difficult and challenging. I am sure that this test will become an important tool for both oncologists and pathologists in obtaining the right diagnosis in these patients.”
Mesothelioma is a rare cancer usually associated with frequent exposure to asbestos. This disease takes about 20 to 60 years for a person to notice they even have it.
There are around 14 in a million people who are diagnosed with mesothelioma a year. The most common association is with occupational and environmental exposure to asbestos.
Rosetta Genomics is offering the miRview(TM) meso in its clinical lab in Philadelphia, PA. The company has about 16 million dollars in cash and expects to perform about 2,000 tests this new year at the Philadelphia clinic.
Mesothelioma is a deadly disease. If you or someone close to you has been diagnosed with Mesothelioma, you may want to contact the attorneys at Childers & Schlueter, LLP to see how they can help protect your legal rights.
Comments for this article are closed.